Mechanistically, being expressed by various cells of the tumor microenvironment, PAR2 promotes both survival and proliferation of cancer cells and dampens the anti-cancer immune response. Domain Therapeutics has developed a novel PAR2 inhibitor, DT-9045, with best-in-class properties. Indeed, ...
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer NEJM Evidence (2022), Article EVIDoa2200043 Google Scholar [4] S. Carreira, et al. Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B TrialPredictive biomarkers for PARP inhibition in prostat...
The approval of this combination comes on the heels of theapproval of another PARP inhibitor, Zejula (niraparib), which is indicated as a monotherapy for the initial maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. ...
Lynparza, a targeted cancer treatment, is classified as a PARP (or Poly ADP-ribose polymerase) inhibitor. PARP inhibitors like Lynparza generally do not cause hair loss. Hair loss has not been reported as a side effect of Lynparza in the package insert and clinical studies conducted by th...
Darinaparsin (ZIO-101) 是一种有机砷,是一种线粒体靶向剂。Darinaparsin 可诱导癌细胞凋亡 (apoptosis),并具有抗癌作用。 DarinaparsinChemical Structure CAS No. :69819-86-9 *Please selectQuantitybefore adding items. 所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务...
results published in theNew England Journal of Medicinein 2021. The drug, according to Merck, is the first and only PARP inhibitor—a type of medication that “causes a disruption in the way that [patients’] cells work,” Marks explains—to improve overall survival in earl...
Learn more about LYNPARZA® (olaparib) as a PARP inhibitor for certain patients with certain types of Ovarian, Breast, Prostate or Pancreatic Cancer.
The treatment is the only PARP inhibitor with positive Phase III results in four different cancer types - ovarian, breast, pancreatic and prostate.
The approval is based on the results of the POLO Phase 3 trial which showed LYNPARZA demonstrated a statistically significant and clinically meaningful improvement in PFS versus placebo in patients with gBRCAm metastatic pancreatic cancer. LYNPARZA is the first and only PARP inhibito...
LYNPARZA became the first and only PARP inhibitor to demonstrate a survival benefit in germline BRCA-mutated, HER2-negative and high-risk early-stage breast cancer. To see this benefit continue at six years of follow-up is tremendous for patients and reinforces how LYNPARZA is continuing...